Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 37INDUSTRY 11NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Gynecologic 1

Conditions

Lymphoma 43Breast Neoplasms 37Lymphoma, Large B-Cell, Diffuse 29Sarcoma 20Lymphoma, Non-Hodgkin 17Burkitt Lymphoma 16Neuroblastoma 15Leukemia 13HIV Infections 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Hodgkin Disease 11Acquired Immunodeficiency Syndrome 11Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 9Ovarian Neoplasms 9Multiple Myeloma 9Carcinoma, Hepatocellular 9Lymphoma, Large-Cell, Immunoblastic 8Lymphoma, Follicular 8Liver Neoplasms 8Liposarcoma 7Breast Neoplasms, Male 7Lymphoma, Mantle-Cell 6Lymphoma, Large-Cell, Anaplastic 6Fallopian Tube Neoplasms 6Sarcoma, Kaposi 5Neoplasms, Plasma Cell 5Lymphoma, B-Cell 5Lung Neoplasms 5Histiocytoma, Malignant Fibrous 5Fibrosarcoma 5

Interventions

Specimen Handling 14Magnetic Resonance Spectroscopy 11Taxes 9Biopsy 9veliparib 7Paclitaxel 7Carboplatin 7pembrolizumab 3olaparib 3Cyclophosphamide 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3(2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone 3talazoparib 2eribulin 2entinostat 2cediranib 2Radiotherapy 2Radiation 2Platinum 2Nivolumab 2Irinotecan 2Immunoglobulin G 2Gemcitabine 2Doxorubicin 2Disulfides 2Cisplatin 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 21,2-diaminocyclohexaneplatinum II citrate 2tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Triple Negative Breast Neoplasms × Doxorubicin × Clear all
NCT00861705 2025-09-30

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Completed
454 enrolled 23 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

NCT01145430 2017-12-22

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
45 enrolled
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡